Ming & worktoplay....
Regarding the test you two were just referring to.....
What is your opinion regarding the previous Orchid (now Bechman) contract, with DNAP now going to be majority owner of Biofrontera?
Do you think DNAP could now just let Biofrontera "know" their platform, and reap the benefits of being a pharma through being majority owner of them??
I've been curious as to how this will be managed. Of course if I remember correctly, there was a 6 month stipulation in that contract, and it was specific to non DNAP generated products.
Have a nice day
66fan
News 
Market Data 
Discover 
